Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY:NVS)

115.77 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Jun 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 301
Open 115.77
Bid (Size) 116.19 (8)
Ask (Size) 116.25 (4)
Prev. Close 115.77
Today's Range 115.77 - 115.77
52wk Range 96.06 - 120.92
Shares Outstanding N/A
Dividend Yield 3.45%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
NOVARTIS AG-SPONSORED ADR (NYSE:NVS) – A Solid Value Pick in Pharmaceuticals
NOVARTIS AG (NYSE:NVS) offers strong profitability, solid financial health, and an attractive valuation, making it a potential value pick in the pharmaceuticals sector. 
Via Chartmill
Novo Nordisk Moves Amycretin Into Phase 3 Trials For Weight Management, Becomes Europe's Largest Company
Novo Nordisk will begin phase 3 trials for amycretin in early 2026 following promising weight loss data and regulatory discussions. 
Via Benzinga

Performance

YTD
+19.2%
+19.2%
1 Month
+2.7%
+2.7%
3 Month
+4.2%
+4.2%
6 Month
+17.6%
+17.6%
1 Year
+8.2%
+8.2%

More News

Read More
Novartis' Fabhalta Delivers Hemoglobin Gains, Reduces Fatigue In Patients With Rare Blood Disorder
Via Benzinga
PU Prime Broadens Portfolio with New Global Indices
Via GlobePRwire
Topics Derivatives Economy
Exposures Derivatives Economy
Is Novartis Gaining or Losing Market Support?
Via Benzinga
Global Billion Dollar Oncology Industry Experiencing Substantial Growth Driven by Increasing Cancer Incidences
Via FinancialNewsMedia
Topics Artificial Intelligence
Exposures Artificial Intelligence
2 Dividend Growth Stocks to Buy and Hold Forever
Via The Motley Fool
Topics Intellectual Property
Exposures Intellectual Property
Rapt Therapeutics Get A Bullish Recommendation On ‘Significant Opportunity’ For Allergy Drug Candidate: Retail Worries About Cash Position
Via Stocktwits
Topics ETFs
Global Billion Dollar Oncology Industry Experiencing Substantial Growth Driven by Increasing Cancer Incidences
From FN Media Group LLC
Via GlobeNewswire
Alcon Secures First FDA Approval Since Novartis Spin-Off In 2019
Via Benzinga
Exposures Product Safety
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
The Smartest Vanguard ETF to Buy With $500 Right Now
Via The Motley Fool
Topics ETFs
Prediction: This "Magnificent Seven" Stock Will Be the Most Valuable Company in the World in 10 Years
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Lazard Transforms Mutual Fund Into IEQ ETF Amid Rising Demand For International Stocks
Via Benzinga
Topics ETFs
Sanofi To Navigate Tariff Impact With $20 Billion In Spending Through 2030
Via Benzinga
Here's My Favorite High-Dividend ETF to Buy Right Now
Via The Motley Fool
Topics ETFs
Trump’s ‘Most Favored Nation’ Drug Plan Likely To Face Pushback, JP Morgan Analysts Say
Via Stocktwits
Topics ETFs Government Stocks
Exposures Political US Equities
S&P 500, Dow Jones Pharma Stocks Boomerang As Trump Threatens Drug-Price Reform
Via Investor's Business Daily
Topics Government Stocks
Exposures Political US Equities
Protagonist/Johnson & Johnson Partnered Drug Shows Significant Skin Clearance In Pivotal Psoriasis Study
Via Benzinga
FDA Expands Surprise Inspections At Foreign Drug And Food Facilities, Targets Double Standards In Overseas Manufacturing Oversight
Via Benzinga
Exposures Product Safety
BioNTech Appoints Novartis Executive As Finance Chief, Reaffirms 2025 Outlook Focusing on Oncology Expansion
Via Benzinga
Regulus Downgraded By Analysts After $1.7B Novartis Buyout Offer — Street Sees Limited Upside Ahead
Via Stocktwits
Topics Stocks
Exposures US Equities
Humana Does Not Alter 2025 Outlook Despite Sales Miss And Medicare Membership Decline
Via Benzinga
Topics Earnings
Exposures Financial
Novartis To Buy US Kidney Drug Developer Regulus Therapeutics For Around $800 Million
Via Benzinga
AppLovin Stock Tumbles After Edgewater Research Cuts Estimates Citing Rising Competition
Via Stocktwits
Topics Artificial Intelligence
Exposures Artificial Intelligence

Frequently Asked Questions

Is Novartis AG Common Stock publicly traded?
Yes, Novartis AG Common Stock is publicly traded.
What exchange does Novartis AG Common Stock trade on?
Novartis AG Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Novartis AG Common Stock?
The ticker symbol for Novartis AG Common Stock is NVS on the New York Stock Exchange
What is the current price of Novartis AG Common Stock?
The current price of Novartis AG Common Stock is 115.77
When was Novartis AG Common Stock last traded?
The last trade of Novartis AG Common Stock was at 06/20/25 07:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.